Persistent neuropathy after treatment with cisplatin and oxaliplatin

Authors

  • Elke E. M. Brouwers Department of Pharmacy & Pharmacology, Slotervaart Hospital/The Netherlands Cancer Institute, Louwesweg 6, 1066, EC, Amsterdam, The Netherlands
  • Alwin D. R. Huitema Department of Pharmacy & Pharmacology, Slotervaart Hospital/The Netherlands Cancer Institute, Louwesweg 6, 1066, EC, Amsterdam, The Netherlands
  • Willem Boogerd Department of Pharmacy & Pharmacology, Slotervaart Hospital/The Netherlands Cancer Institute, Louwesweg 6, 1066, EC, Amsterdam, The Netherlands; Department of Medical Oncology and Neuro-oncology, Antoni van Leeuwenhoek Hospital/The Netherlands Cancer Institute, Plesmanlaan 121, 1066, CX, Amsterdam, The Netherlands
  • Jos H. Beijnen Department of Pharmacy & Pharmacology, Slotervaart Hospital/The Netherlands Cancer Institute, Louwesweg 6, 1066, EC, Amsterdam, The Netherlands; Beta faculty, Department of Pharmaceutical Sciences, Division of Biomedical Analysis, Section of Drug Toxicology, Utrecht University, P.O. Box 80082, 3508, TB, Utrecht, The Netherlands
  • Jan H. M. Schellens Department of Medical Oncology and Neuro-oncology, Antoni van Leeuwenhoek Hospital/The Netherlands Cancer Institute, Plesmanlaan 121, 1066, CX, Amsterdam, The Netherlands; Beta faculty, Department of Pharmaceutical Sciences, Division of Biomedical Analysis, Section of Drug Toxicology, Utrecht University, P.O. Box 80082, 3508, TB, Utrecht, The Netherlands

DOI:

https://doi.org/10.1080/02841860902806609

Abstract

Background. The aims of the current explorative study were to assess persistent neuropathy in 45 patients up to 6 years after treatment with cisplatin or oxaliplatin and to determine the most adequate method to evaluate neuropathy. Furthermore, the effect of possible determinants on persistent neuropathy was investigated. Material andmethods. The assessment of neuropathy was performed using a questionnaire, by neurological tests, and by vibration threshold (VT) measurements. Because VT determination gives the most objective information, VT measurements were used for further analyses. Results and discussion. The analyses revealed that neuropathy of the hands was related to follow-up time, with an observed recovery half-life of 6.8 (± 3.1) years. No significant reversibility of neuropathy of the feet within the observation period could be demonstrated. For cisplatin, the severity of neuropathy was related to the cumulative dose and sodium thiosulfate use. Oxaliplatin induced neuropathy did not appear to be related to the dose within the studied dose range. No relationship with platinum levels, renal function, glutathione transferase genotypes, diabetes mellitus, alcohol use, or co-medication could be demonstrated. This study was performed as an explorative study and the issues discussed need to be investigated further.

Downloads

Download data is not yet available.

Downloads

Published

2009-01-01

How to Cite

Brouwers, E. E. M., Huitema, A. D. R., Boogerd, W., Beijnen, J. H., & Schellens, J. H. M. (2009). Persistent neuropathy after treatment with cisplatin and oxaliplatin. Acta Oncologica, 48(6), 832–841. https://doi.org/10.1080/02841860902806609